Halozyme Therapeutics, Inc. (HALO)
68.52
-0.46
(-0.67%)
USD |
NASDAQ |
May 21, 16:00
68.52
0.00 (0.00%)
After-Hours: 19:59
Halozyme Therapeutics Research and Development Expense (TTM) : 92.25M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.891B |
| Agenus, Inc. | 69.64M |
| Inovio Pharmaceuticals, Inc. | 50.82M |
| Curis, Inc. | 26.16M |
| LadRx Corp. | 0.7712M |